🎉 M&A multiples are live!
Check it out!

Assertio Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Assertio Therapeutics and similar public comparables like Galapagos, Benevolent AI, and Vivoryon Therapeutics.

Assertio Therapeutics Overview

About Assertio Therapeutics

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.


Founded

1995

HQ

United States of America
Employees

58

Website

assertiotx.com

Financials

LTM Revenue $122M

LTM EBITDA $15.7M

EV

-$0.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Assertio Therapeutics Financials

Assertio Therapeutics has a last 12-month revenue of $122M and a last 12-month EBITDA of $15.7M.

In the most recent fiscal year, Assertio Therapeutics achieved revenue of $125M and an EBITDA of $6.9M.

Assertio Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Assertio Therapeutics valuation multiples based on analyst estimates

Assertio Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $152M $125M XXX XXX XXX
Gross Profit $137M $125M XXX XXX XXX
Gross Margin 90% 100% XXX XXX XXX
EBITDA -$223M $6.9M XXX XXX XXX
EBITDA Margin -147% 6% XXX XXX XXX
Net Profit $110M -$332M XXX XXX XXX
Net Margin 72% -266% XXX XXX XXX
Net Debt $1.9M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Assertio Therapeutics Stock Performance

As of April 15, 2025, Assertio Therapeutics's stock price is $1.

Assertio Therapeutics has current market cap of $59.6M, and EV of -$0.7M.

See Assertio Therapeutics trading valuation data

Assertio Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$0.7M $59.6M XXX XXX XXX XXX $-0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Assertio Therapeutics Valuation Multiples

As of April 15, 2025, Assertio Therapeutics has market cap of $59.6M and EV of -$0.7M.

Assertio Therapeutics's trades at -0.0x LTM EV/Revenue multiple, and -0.0x LTM EBITDA.

Analysts estimate Assertio Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Assertio Therapeutics and 10K+ public comps

Assertio Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$0.7M XXX XXX XXX
EV/Revenue -0.0x XXX XXX XXX
EV/EBITDA -0.1x XXX XXX XXX
P/E -2.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Assertio Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Assertio Therapeutics Valuation Multiples

Assertio Therapeutics's NTM/LTM revenue growth is -3%

Assertio Therapeutics's revenue per employee for the last fiscal year averaged $2.2M, while opex per employee averaged $1.8M for the same period.

Over next 12 months, Assertio Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Assertio Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Assertio Therapeutics and other 10K+ public comps

Assertio Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -18% XXX XXX XXX XXX
EBITDA Margin 6% XXX XXX XXX XXX
EBITDA Growth -103% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 3% XXX XXX XXX XXX
Revenue per Employee $2.2M XXX XXX XXX XXX
Opex per Employee $1.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 3% XXX XXX XXX XXX
Opex to Revenue 84% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Assertio Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Assertio Therapeutics M&A and Investment Activity

Assertio Therapeutics acquired  XXX companies to date.

Last acquisition by Assertio Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Assertio Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Assertio Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Assertio Therapeutics

When was Assertio Therapeutics founded? Assertio Therapeutics was founded in 1995.
Where is Assertio Therapeutics headquartered? Assertio Therapeutics is headquartered in United States of America.
How many employees does Assertio Therapeutics have? As of today, Assertio Therapeutics has 58 employees.
Who is the CEO of Assertio Therapeutics? Assertio Therapeutics's CEO is Mr. Brendan P. O’Grady.
Is Assertio Therapeutics publicy listed? Yes, Assertio Therapeutics is a public company listed on NAS.
What is the stock symbol of Assertio Therapeutics? Assertio Therapeutics trades under ASRT ticker.
When did Assertio Therapeutics go public? Assertio Therapeutics went public in 1997.
Who are competitors of Assertio Therapeutics? Similar companies to Assertio Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Assertio Therapeutics? Assertio Therapeutics's current market cap is $59.6M
What is the current revenue of Assertio Therapeutics? Assertio Therapeutics's last 12-month revenue is $122M.
What is the current EBITDA of Assertio Therapeutics? Assertio Therapeutics's last 12-month EBITDA is $15.7M.
What is the current EV/Revenue multiple of Assertio Therapeutics? Current revenue multiple of Assertio Therapeutics is -0.0x.
What is the current EV/EBITDA multiple of Assertio Therapeutics? Current EBITDA multiple of Assertio Therapeutics is -0.0x.
What is the current revenue growth of Assertio Therapeutics? Assertio Therapeutics revenue growth between 2023 and 2024 was -18%.
Is Assertio Therapeutics profitable? Yes, Assertio Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.